Shares of Reata Pharmaceuticals plunged more than 33 percent after the company announced a potential delay in plans to seek approval of omaveloxolone, an investigational treatment of Friedreich’s ataxia (FA).
https://www.pharmalive.com/wp-content/uploads/2020/08/Reata-Pharmaceuticals-Sees-Hiccup-in-Filing-for-Approval-of-FA-Drug-BioSpace-8-11-20.jpeg350625Andrew Humphreyshttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngAndrew Humphreys2020-08-11 12:04:562020-08-11 16:30:18Potential Delay in Filing for Approval of Reata Pharmaceuticals’ FA Drug